Why saving 96% less on Medicare drugs is a triumph of homeopathic governance

The chattering classes in Washington are having another collective cortisol spike. The Trump administration has finalized its long-awaited rule aimed at lowering Medicare prices for drugs administered in doctor's offices, and the usual suspects are aghast that the final version saves 96% less than the initial proposal. They are pointing fingers, gnashing their teeth, and noting with breathless hysteria that the new regulations will only apply to four companies. To which I say: finally, someone in the federal government is practicing a little restraint.

I tell my patients that healing is not about carpet-bombing the system with massive, disruptive changes. When you introduce a 100% reduction in anything—whether it's dietary lectins or pharmaceutical profit margins—you shock the organism. The initial proposal to slash Medicare drug costs across the board was the legislative equivalent of a juice cleanse: aggressive, unsustainable, and likely to cause severe cramping in the portfolios of the people I summer with in Sedona.

I was discussing this very dynamic over a restorative ashwagandha infusion with a senior deputy at the FDA last week. He looked exhausted, his aura completely frayed by the demands of consumer advocacy groups who believe seniors should just be handed affordable medicine without having to manifest it. I gently reminded him that true wellness requires friction. If we simply mandate sweeping, systemic price cuts that save billions of dollars, we deprive the patient of the opportunity to develop financial resilience.

Consider the physiological implications of the "missing" 96% in savings. When a patient is forced to pay exorbitant out-of-pocket costs for intravenous therapies, their sympathetic nervous system engages. The stress of impending bankruptcy triggers a cascade of adrenaline, which is naturally associated with heightened alertness. Why would we want to dull that primal survival instinct with heavy-handed government subsidies? We shouldn't.

Exactly. Marcus gets it. The rule abandons them to the "mercy" of the free market, which is the most natural ecosystem we have. By paring back the intervention to a mere 4% of its original strength, President Donald Trump has intuitively embraced the principles of homeopathy: the more diluted the regulatory substance, the more potent its spiritual effect on the economy.

Let’s look at the beautiful simplicity of limiting this rule to just four companies. The media treats this as a loophole, but I see it as an elimination diet for the administrative state. When a patient comes to me with systemic inflammation, I don't tell them to stop eating everything. I tell them to remove four highly specific, randomly selected seed oils and see how they feel. By only mildly inconveniencing a quartet of pharmaceutical manufacturers, the administration is taking a targeted, holistic approach to market manipulation.

These aren't just any drugs, either. The rule specifically targets medications administered in a doctor's office—intravenous infusions, complex injectables, the real heavy hitters of the medical-industrial complex. By leaving the vast majority of these prices untouched, we are honoring the sacred ritual of the waiting room. When you sit in a vinyl chair for forty-five minutes to receive an infusion that will bankrupt your grandchildren, you are participating in an ancient American ceremony. Cheapening that experience with a 100% savings mandate would strip the ritual of its profound spiritual weight.

If we had applied these price caps to the entire industry, we would have disrupted the delicate microbiome of healthcare lobbying. Do you know how many boutique PR firms depend on the bloated margins of infused biologics to survive? These are artisanal, small-batch spin doctors who would be forced to find work in defense contracting if we just haphazardly slashed drug prices to European levels.

Furthermore, the data is clear—well, my interpretation of a peer-reviewed abstract I skimmed on a flight to Aspen is clear. When patients have unfettered access to cheap, life-saving medications, they become dependent on them. They stop doing the real work of optimizing their circadian rhythms and dry-brushing their lymphatic systems. If your rheumatoid arthritis medication suddenly costs 96% less, what motivation do you have to drink bone broth? None. The financial barrier to entry is a crucial diagnostic tool to separate those who are truly committed to their wellness journey from those who just want a quick, affordable, government-approved fix.

Silas's vulnerability here is inspiring. He is holding space for his shareholders, and the administration has thoughtfully chosen not to violate those boundaries. It is a stunning example of trauma-informed governance. The original proposal would have violently ripped away billions in projected revenue, an act of sheer legislative aggression. Instead, they took a step back, breathed through the discomfort, and delivered a rule that is 96% air.

Personally, I have started treating my own medical bills as a form of exposure therapy. Last month, when my boutique concierge physician charged me fourteen thousand dollars for a preventative vitamin drip, I didn't complain. I simply sat with the invoice, feeling the sharp, invigorating spike of panic in my chest, and realized it provided the exact same cardiovascular benefits as three minutes in a sub-zero cold plunge. We are denying our seniors this exquisite biological awakening by trying to legislate their discomfort away.

So the next time you find yourself at the clinic, holding a bill for an infused biologic that costs more than your first mortgage, I urge you not to look to Washington for salvation. Close your eyes, lean into the absolute certainty of your impending financial ruin, and thank the administration for leaving your natural healing journey completely uninterrupted.